1.XuY, Li W, Gan J, HeX,Huang X. An analysis of sintilimab
combined with ruxolitinib ascompassionate therapy for 12 adults with
EBV-associatedhemophagocytic lymphohistiocytosis. Ann Hematol [Internet]. 2023
Oct3
3.ZhouF, Pan T, Li X, Du F, Ma X, HeX,et al. Exploration of
efficacy and safety of combined therapy ofbasiliximab with ruxolitinib for grade
3-4 steroid-refractory acutegraft-versus-host disease: a registered clinical
trial (NCT05021276).Bone Marrow Transplant. 2023 Aug;58(8):959–61.
4.SongY, Li X, HeX,Zhou F, Du F, Wang Z, et al. Dose-escalating
ruxolitinib forrefractory hemophagocytic lymphohistiocytosis. Front Immunol.
2023Jun 29;14:1211655.
5.ZhouL, HeX,Wang Y, Zhou F, Ma X. Elevated troponin in
hematopoietic stem celltransplantation-associated thrombotic microangiopathy: a
case report.Thrombosis Update. 2020;1.
6.HeX,Wang Q, Cen J, Qiu H, Sun A, Chen S, et al. Predictive
value of highEVI1 expression in AML patients undergoing myeloablative
allogeneichematopoietic stem cell transplantation in first CR. Bone
MarrowTransplant. 2016 Jul;51(7):921–7.
